Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorXijing Hospital
About this trial
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
available for 5 years of follow-up study
Disqualifiers
Death caused other than cardiovascular and cerebralvascular diseases till the study ends
Floating Population
Pregnancy, lactation, or child bearing women
Tumor
Trial population
volunteer
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
30,000 Participants
are grouped into 1 trial groupGroup A: volunteer
Trial outcomes
Primary outcomes
1
Number of Participants with major adverse events
Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.
Time frame
5 yearsSecondary outcomes
1
blood routine, glucose and lipid profile; ECG;
the tests mentioned above will be taken once per year
Time frame
5 years2
serum adiponectin concentration, activity and isoforms
serum adiponectin concentration, activity and isoforms will be monitored once per year.
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov